Analyzing novel immunological target molecules of the TIGIT axis and the purinergic pathway, an increased frequency of CD8+ T cells co-expressing TIGIT with PVRIG or CD39 was characteristic for all BM aspirates, in contrast to NMC. This evidence concerns the gene CD8A and nut midline carcinoma.